Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy

被引:4
|
作者
Zhai, Xiaoqian [1 ]
Wu, Qiang [1 ]
Pu, Dan [1 ]
Yin, Liyuan [1 ]
Wang, Weiya [2 ]
Zhu, Daxing [1 ]
Xu, Feng [1 ]
机构
[1] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Pathol Dept, Chengdu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ALK fusion; ALK-GCA and EML4-ALK; stage IIIB-N2 NSCLC; alectinib; adjuvant targeted therapy; POSTOPERATIVE RADIOTHERAPY; CANCER; CRIZOTINIB; CHEMOTHERAPY; SURVIVAL;
D O I
10.3389/fonc.2021.782682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLCs) have favorable and impressive response to ALK tyrosine kinase inhibitors (TKIs). However, ALK rearrangement had approximately 90 distinct fusion partners. Patients with different ALK fusions might have distinct responses to different-generation ALK-TKIs. In this case report, we identified a novel non-reciprocal ALK fusion: ALK-grancalcin (GCA) (A19: intragenic) and EML4-ALK (E20: A20) by next-generation sequencing (NGS) in a male lung adenocarcinoma patient who was staged as IIIB-N2 after surgery. After a multidisciplinary discussion, the patient received alectinib adjuvant targeted therapy and postoperative radiotherapy (PORT). He is currently in good condition, and disease-free survival (DFS) has been 20 months so far, which has been longer than the median survival time of IIIB NSCLC patients. Our study extended the spectrum of ALK fusion partners in ALK + NSCLC, and we reported a new ALK fusion: ALK-GCA and EML4-ALK and its sensitivity to alectinib firstly in lung cancer. It is vital for clinicians to detect fusion mutations of patients and report timely the newfound fusions and their response to guide treatment.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report
    Liang, Qi
    Xu, Huanhuan
    Liu, Yiqian
    Zhang, Weiming
    Sun, Chongqi
    Hu, Meng
    Zhu, Yizhi
    Tan, Shanyue
    Xu, Xian
    Wang, Sumeng
    Liu, Lingxiang
    [J]. LUNG CANCER, 2021, 162 : 86 - 89
  • [2] Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report
    Wu, Xueqian
    Wang, Weiya
    Zou, Bingwen
    Li, Yanying
    Yang, Xiaojuan
    Liu, Ning
    Ma, Qizhi
    Zhang, Xiaoxuan
    Wang, Yongsheng
    Li, Dan
    [J]. THORACIC CANCER, 2020, 11 (06) : 1695 - 1698
  • [3] A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib
    Zhong, Jiang-Ming
    Zhang, Gui-Feng
    Lin, Li
    Li, De-Yu
    Liu, Zhen-Hua
    [J]. LUNG CANCER, 2020, 145 : 211 - 212
  • [4] Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma
    Jiang, Liqun
    Chen, Suping
    Stinnett, Victoria
    Haley, Lisa
    Morsberger, Laura
    Shane, Alison
    Hardy, Melanie
    Smith, Kirstin
    Gocke, Christopher D.
    Lin, Ming-Tseh
    Zhou, Ying S.
    [J]. CANCER GENETICS, 2021, 258 : 18 - 22
  • [5] Identification of a Novel EML4-ALK Fusion Transcript in Lung Adenocarcinoma
    To, K.
    Tong, J. H. M.
    Law, P. P. Y.
    Chau, S. L.
    Lung, R. W. M.
    Yeung, S. F.
    Kang, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S218 - S219
  • [6] Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant
    Song, Peng
    Zhang, Jingcheng
    Shang, Congcong
    Zhang, Li
    [J]. THORACIC CANCER, 2018, 9 (10) : 1327 - 1332
  • [7] A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib A case report
    Guo, Jun
    Shi, Junping
    Yao, Ming
    Jin, Yi
    Liu, Dengxiang
    Liu, Weiling
    Wang, Kai
    Jiang, Da
    [J]. MEDICINE, 2020, 99 (45) : E22631
  • [8] Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
    Liu, Di
    Xu, Xinyan
    Wen, Junmiao
    Zhang, Chi
    Fan, Min
    [J]. LUNG CANCER, 2021, 160 : 32 - 35
  • [9] Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report
    Wang, Mingting
    Gong, Yifan
    Cheng, Yun
    Yang, Lei
    Wang, Wenhui
    Lei, Xiaolin
    [J]. ONCOLOGY LETTERS, 2022, 24 (04)
  • [10] Primary lung adenocarcinoma with breast metastasis harboring the EML4-ALK fusion: A case report
    Zhang, Wenwen
    Zhang, Yu
    Zhou, Lei
    Tan, Na
    Bai, Yuju
    Xing, Shiyun
    [J]. ONCOLOGY LETTERS, 2024, 27 (06)